PMID- 34390338
OWN - NLM
STAT- MEDLINE
DCOM- 20220218
LR  - 20220218
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 107
IP  - 1
DP  - 2022 Jan 1
TI  - The Unfavorable Impact of DR9/DR9 Genotype on the Frequency and Quality of 
      Partial Remission in Type 1 Diabetes.
PG  - e293-e302
LID - 10.1210/clinem/dgab589 [doi]
AB  - CONTEXT: Partial remission (PR) is a specific stage in type 1 diabetes (T1D). 
      Although human leukocyte antigen (HLA) class II loci are the strongest genetic 
      determinants in T1D, the relationship between PR and HLA remains unclear. 
      OBJECTIVE: To investigate the association between PR status and HLA genotypes in 
      patients with T1D. METHODS: A total of 237 patients with T1D were included. PR 
      was defined according to C-peptide >/=300 pmol/L. The frequency of PR and peak 
      C-peptide levels during remission phase were compared according to HLA status. 
      Clinical characteristics including age of onset and diabetes autoantibodies were 
      collected. All analyses were duplicated when subjects were divided into 
      childhood- and adult-onset T1D. RESULTS: The median follow-up time was 24 months, 
      65.8% (156/237) of patients with T1D went into PR. DR9/DR9 carriers had a lower 
      PR rate (44.2% vs 70.6%, P = .001) and were less likely to enter PR (OR = 0.218, 
      95% CI 0.098-0.487, P < .001) than the non-DR9/DR9 carriers, observed in both 
      childhood- and adult-onset T1D. Besides, the peak C-peptide level during PR phase 
      was also lower in DR9/DR9 carriers, and more notable in adult-onset T1D. When 
      compared with non-DR9/DR9 carriers, T1D with DR9/DR9 genotype presented an older 
      age of onset and a lower positivity of zinc transporter 8 antibody (ZnT8A), and 
      the lower trend of ZnT8A was only found in adult-onset T1D (P = .049). 
      CONCLUSION: Patients with T1D carrying susceptible DR9/DR9 are less prone to 
      undergo PR. Additionally, the recovery extent of beta-cell function during the PR 
      phase tends to be lower in adults carrying DR9/DR9, which might be associated 
      with ZnT8A.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the 
      Endocrine Society. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Chen, Yan
AU  - Chen Y
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, and 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha 410011, Hunan, China.
FAU - Xia, Ying
AU  - Xia Y
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, and 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha 410011, Hunan, China.
FAU - Xie, Zhiguo
AU  - Xie Z
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, and 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha 410011, Hunan, China.
FAU - Zhong, Ting
AU  - Zhong T
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, and 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha 410011, Hunan, China.
FAU - Tang, Rong
AU  - Tang R
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, and 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha 410011, Hunan, China.
FAU - Li, Xia
AU  - Li X
AUID- ORCID: 0000-0001-8665-7983
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, and 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha 410011, Hunan, China.
FAU - Zhou, Zhiguang
AU  - Zhou Z
AUID- ORCID: 0000-0002-0374-1838
AD  - National Clinical Research Center for Metabolic Diseases, Key Laboratory of 
      Diabetes Immunology (Central South University), Ministry of Education, and 
      Department of Metabolism and Endocrinology, The Second Xiangya Hospital of 
      Central South University, Changsha 410011, Hunan, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03610984
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Autoantibodies)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Insulin)
RN  - 0 (SLC30A8 protein, human)
RN  - 0 (Zinc Transporter 8)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age of Onset
MH  - Aged
MH  - Autoantibodies/blood/immunology
MH  - Child
MH  - Diabetes Mellitus, Type 1/*diagnosis/drug therapy/genetics/immunology
MH  - Female
MH  - Follow-Up Studies
MH  - Genetic Predisposition to Disease
MH  - Genotyping Techniques
MH  - HLA-DR Antigens/*genetics
MH  - Haplotypes
MH  - Humans
MH  - Insulin/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
MH  - Young Adult
MH  - Zinc Transporter 8/immunology
OTO - NOTNLM
OT  - HLA genotypes
OT  - partial remission
OT  - type 1 diabetes
EDAT- 2021/08/15 06:00
MHDA- 2022/02/19 06:00
CRDT- 2021/08/14 12:05
PHST- 2021/04/07 00:00 [received]
PHST- 2021/08/15 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
PHST- 2021/08/14 12:05 [entrez]
AID - 6352417 [pii]
AID - 10.1210/clinem/dgab589 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2022 Jan 1;107(1):e293-e302. doi: 
      10.1210/clinem/dgab589.